Table 2.
Particulate System | Drug | Administration Scheme (Cell Line/Strategy) |
Observations | Ref | |
---|---|---|---|---|---|
NATURAL POLYMERS | Chitosan MPs | INH RFB |
A549, THP-1 Mφ AI with Mb BCG |
|
[104] |
Chitosan NPs | Anti-Cystatin C siRNA | HMDM, THP-1 Mφ BI with Mtb H37Rv and susceptible and resistant isolates |
|
[105] | |
Fucoidan MPs | RFB INH |
A549, THP-1 Mφ AI with Mb BCG |
|
[106] | |
Glucan NPs | RFB | J774 AI with Mtb H37Ra |
|
[107] | |
SYNTHETIC POLYMERS | PLGA NPs | RIF | RAW 264.7, BMDM BI with Mb BCG |
|
[108] |
PLGA NPs | RIF INHP |
HMDM BI with Ms |
|
[109] | |
PLGA NPs encapsulated inside MAAEA MPs |
RIF | Caco2, MH-S AI with Mtb H37Rv |
|
[110] | |
Poly(ε-caprolactone) | INH SQ641 + CsA + VE |
J774A.1 AI with Mtb H37Rv |
|
[111] | |
Poly(ethylene sebacate) NPs | RIF-CUR | RAW 264.7 AI with Mtb H37Rv |
|
[112] |
NPs: nanoparticles; MPs: microparticles; PLGA: poly(lactic-co-glycolic) acid; MAAEA: methacrylic acid–ethyl acrylate copolymer; RIF: rifampicin; INHP: pentenyl–isoniazid; INH: isoniazid; SQ641 + CsA + VE: natural analogue of capuramycin + cyclosporine A + vitamin E; RFB: rifabutin; CUR: curcumin; BI: before infection; AI: after infection; BMDM: bone-marrow-derived monocytes; HMDM: human-monocyte-derived macrophages; Ms: Mycobacterium smegmatis; Mb: Mycobacterium bovis.